Correlation between elevated Lp(a) levels and cardiovascular risk in coronary heart disease patients with different homocysteine concentrations Authors: Tao Sun, Wenhao Zhang, Pingyan Fei, Yueping Shi, Xuelian Zhang Published: 2026 ABSTRACT BackgroundIn recent years, the impact of lipoprotein(a) (Lp(a)) on the prognosis of coronary heart disease has been increasingly recognized. Lp(a) is an independent risk factor for cardiovascular disease, and studies have shown that homocysteine (HCY) may influence the association between Lp(a) and the risk of recurrent cardiovascular events. This study investigates the association between Lp(a) levels and recurrent cardiovascular events in patients with varying HCY concentrations.MethodsWe conducted a 36-month follow-up on 530 patients with coronary heart disease and divided them into low-Lp(a) and high-Lp(a) groups based on Lp(a) levels. The incidence rates of major adverse cardiovascular events (MACE) and acute coronary events (ACE) were compared between the two groups. The association between elevated Lp(a) and cardiovascular risk in different subgroups(based on HCY concentration) was analyzed using Kaplan-Meier curves and Cox proportional hazards models.ResultsElevated Lp(a) remained a significant risk factor for both MACE (HR = 2.07, 95% CI = 1.37–3.12, P = 0.001) and ACE (HR = 2.83, 95% CI = 1.67–4.81, P = 0.001) overall. In subgroup analyses, elevated Lp(a) in patients with moderate-to-high HCY levels constituted a high-risk cohort for MACE and ACE occurrence (HR = 1.87, 95% CI = 1.01–3.46, P = 0.046;HR = 2.85, 95% CI = 1.32–6.18, P = 0.008). Among those with low HCY levels, elevated Lp(a) showed no association with either MACE or ACE (P > 0.05).ConclusionWhen HCY is elevated, patients with increased Lp(a) experience amplified risk of recurrent cardiovascular events. This association shifts when HCY is at low levels. Future efforts should emphasize combined assessment of Lp(a) and HCY and explore targeted intervention strategies to reduce residual cardiovascular risk.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12872-026-05847-0. Introduction Cardiovascular disease (CVD) is an escalating global health threat, with projections estimating 35.6 million cardiovascular deaths by 2050. Research indicates that the prevalence of CVD will increase by 31.1% by 2060 compared to 2025 [1, 2]. Among the various forms of CVD, coronary artery disease (CAD) presents a particularly significant public health challenge in China. As socioeconomic development and lifestyle changes continue, the incidence of CAD is increasingly affecting younger populations [3, 4]. Despite receiving standard revascularization and secondary prevention therapies, survivors of acute coronary syndrome (ACS) remain at high risk of recurrence, with approximately 9.2% experiencing recurrent ACS within one year [5]. Therefore, early and accurate identification of the risk of recurrent cardiovascular events in CAD patients is critical for guiding treatment strategies and improving long-term outcomes. In recent years, there has been a growing shift in focus regarding risk factors influencing the prognosis of CAD. While traditional risk factors such as age, smoking, diabetes, and low-density lipoprotein cholesterol (LDL-C) levels remain important, increasing attention is now being given to non-traditional factors, including lipoprotein(a) (Lp(a)) and homocysteine (HCY). Lp(a) is a complex protein consisting of apolipoprotein(a), apolipoprotein B-100, and lipids such as cholesterol, phospholipids, and triglycerides [6]. Current research suggests that Lp(a) contributes to atherosclerosis, inflammation, and thrombosis, positioning it as an independent risk factor for CAD. Homocysteine, a sulfur-containing amino acid derived from the demethylation of methionine, shares chemical properties with cysteine [7]. Elevated HCY levels are well recognized as a risk factor for atherosclerotic vascular disease and hypercoagulable states, and have been closely linked to an increased risk of cardiovascular events in CAD patients [8–10]. While the harmful effects of elevated HCY and Lp(a) levels on cardiovascular risk are widely recognized, patients in clinical practice often present with multiple concurrent risk factors. This study aims to explore the relationship between elevated Lp(a) levels and cardiovascular risk at varying HCY levels in CAD patients, with the ultimate goal of enhancing risk prediction for recurrent cardiovascular events and optimizing risk stratification. Materials and methods Study population This retrospective analysis included patients with CAD who underwent coronary arteriography at Songjiang District Central Hospital, Shanghai, between January 2019 and May 2022. Participants were divided into two groups based on their initial fasting Lp(a) concentration: Low-Lp(a) (< 300 mg/L) and High-Lp(a) (≥ 300 mg/L). For subgroup analysis, patients were further categorized according to HCY concentration quartiles: S1 (HCY < 8.85 µmol/L), S2 (8.85 ≤ HCY < 15.79 µmol/L), and S3 (HCY ≥ 15.79 µmol/L), the units of measurement for the above data are as specified by the laboratory department of this institution. All patients who underwent percutaneous coronary intervention (PCI) received standard postoperative drug therapy as recommended by national guidelines, including dual antiplatelet therapy (100 mg aspirin and 75 mg clopidogrel or 180 mg ticagrelor) for at least 12 months, followed by lifelong single antiplatelet therapy (100 mg aspirin or 75 mg clopidogrel). Additionally, all patients received lipid-lowering therapy with either 10 mg rosuvastatin or 20 mg atorvastatin. Other medications were prescribed at the discretion of the attending physician (Fig. 1).Fig. 1Study design and patients Study design and patients Inclusion criteria: (1) Meeting ACS diagnostic criteria; (2) Complete follow-up data; (3) Expected survival > 3 years. Exclusion criteria: (1) Echocardiography revealing organic heart disease such as cardiomyopathy, valvular heart disease, cardiac amyloidosis, congenital heart disease, pericardial disease, or ventricular aneurysm; (2) Chronic obstructive pulmonary disease; (3) Renal insufficiency; (4) History of iodine allergy; (5) Patients who discontinued or changed medications without authorization; (6) Loss to follow-up. The study ultimately enrolled 530 patients, including 231 males and 299 females. After 3 years of follow-up (mean duration: 33 months), 93 MACE(Major Adverse Cardiovascular Events) events occurred, including 58 ACE(Acute coronary events) events. Clinical data collection Basic information includes gender, age, history of hypertension, and history of diabetes. All patients undergo fasting blood glucose and lipid profile testing (including lipoprotein a, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum creatinine, Troponin I, and NT-proBNP levels). The Lp(a) assay method is as follows: Use an Lp (a) assay kit (latex-enhanced immunoturbidimetric method) on a fully automated biochemical analyzer (e.g., Hitachi 7020). (1) Reagents and Lp(a) calibration serum are ready to use upon opening; (2). Analytical method: 2-point endpoint method; Wavelength: 600 nm; Sample: 3.0 µL; R-1: 255 µL, R-2: 85 µL; Calibration method: Spline function; Reaction trend: Increasing; Assay Stability: 37.0 °C. After mixing the sample with R-1, add R-2 at 5 min, read absorbance A1 at 340 s, and read absorbance A2 at 10 min. The reaction absorbance is calculated as the calibrated difference between A2 and A1. (3). Result calculation: 5-point calibration using a spline function as the calculation model. A dose-response curve is plotted based on the absorbance values and the calibration serum values; the sample concentration can be calculated from the absorbance value on the dose-response curve. The HCY detection method is as follows: On a fully automated biochemical analyzer (e.g., Hitachi 7020), use a homocysteine assay kit (enzyme cycle method): Take 10 µL of sample and 180 µL of Reagent 1, mix well, and incubate at 37 °C for 3–5 min; Add 50 µL of Reagent 2, mix well, and incubate at 37 °C for 150 s; monitor the change in absorbance for 1–3 min at the measurement wavelength and calculate ΔA/min; use multi-point calibration and fit a multi-parameter curve equation (e.g., logit/log) to determine the HCY concentration from ΔA. The primary endpoint was MACE, which included cardiac death, non-fatal myocardial infarction, ischemic stroke, and unplanned coronary revascularization. Unplanned coronary revascularization encompasses ischemia-driven revascularization and stenosis-driven revascularization. Stenosis-driven revascularization is defined as revascularization performed when angiography demonstrates significant worsening of stenosis without angina symptoms, including (ST-segment elevation myocardial infarction)STEMI, (Non-ST-segment elevation myocardial infarction)NSTEMI, and unstable angina (UA). After recording the patients’ basic information through the electronic medical record system, follow-up was conducted via a combination of outpatient clinic visits, review of inpatient medical records, and telephone follow-ups to monitor medication adherence, lipid control status, and endpoint events. Detailed information was obtained through their attending physicians. The follow-up lasted for a total of 36 months, during which each patient underwent at least two lipid measurements during the post-discharge follow-up period. Echocardiography Echocardiography was performed using a Philips EPIQ 7 C diagnostic ultrasound system (serial number: ZY2020000312) with a probe frequency of 1–5 MHz. Patients were positioned in the left lateral decubitus position. Left ventricular ejection fraction was measured by an experienced echocardiographer with the title of associate chief physician or higher, with three measurements averaged. Coronary angiography CAG: For hemodynamic measurements and cardiac catheterization, the Siemens flat-panel angiography system (Model: Artis Q ceiling, Device serial number: 109868, Device identification number: ZY2020000294) is utilized. Unless otherwise indicated, the right radial artery is typically selected as the puncture site for CAG. Following local infiltration anesthesia, successful radial artery puncture is performed using the Seldinger technique. A 6 F radial artery sheath is then advanced over a super-sliding guidewire, air bubbles within the sheath are thoroughly evacuated, and optimal angiographic positioning is achieved. Angiography is subsequently performed by two experienced associate chief physicians specializing in cardiac catheterization using a 5 F multipurpose catheter. The severity of coronary artery lesions was assessed using American College of Cardiology criteria, with coronary stenosis evaluated via the modified Gensini score [11]. Statistical methods Statistical analysis was performed using SPSS 26.0 software. Quantitative data are presented as mean ± standard deviation, with intergroup comparisons conducted using one-way ANOVA. Qualitative data are expressed as percentages, with intergroup comparisons performed using chi-square tests. Kaplan-Meier curves and the log-rank test were used to compare event-time relationships between groups. Cox proportional hazards models were employed to calculate hazard ratios and 95% confidence intervals for MACE and ACE. All reported p-values in this study were two-sided, with P < 0.05 indicating statistical significance. Results After a follow-up period of 36 months (mean 33 months), this study included a total of 530 patients, consisting of 231 males and 299 females, with a mean age of 65 years. Participants were categorized into two groups based on Lp(a) concentration: Low-Lp(a) (< 300 mg/L) and High-Lp(a) (≥ 300 mg/L). Comparison of baseline characteristics showed no statistically significant differences between the groups in terms of age, gender, or prevalence of hypertension (P > 0.05). Similarly, there were no significant differences in HDL, LDL, total cholesterol, triglycerides, or creatinine levels (P > 0.05). Notably, homocysteine (HCY) concentration was significantly higher in the High-Lp(a) group compared to the Low-Lp(a) group (P = 0.001). The Gensini score, which reflects the degree of coronary artery stenosis, was significantly higher in the High-Lp(a) group compared to the Low-Lp(a) group (P = 0.003) (Table 1). Table 1Baseline characteristics of patients Low-Lp(a)N=353High-Lp(a)N=177 P Male(%)160(45%)71(40%)0.254Age64 ± 11.7365.±11.660.054Hypertension(%)155(44%)82(46%)0.597Diabetes(%)73(21%)41(23%)0.512Creatinine(µmol/L)69.72 ± 14.1469.15 ± 14.860.666Uric Acid(µmol/L)357.92 ± 101.70356.22 ± 100.160.855BUN(mmol/L)5.55 ± 1.905.82 ± 2.120.134Cholesterol(mmol/L)4.25 ± 1.304.39 ± 1.210.221Triglycerides(mmol/L)1.62 ± 1.021.63 ± 1.010.973HDL(mmol/L)1.20 ± 0.371.16 ± 0.330.276LDL(mmol/L)2.69 ± 0.912.85 ± 0.990.065HCY(µmol/L)12.58 ± 5.68a14.52 ± 6.89b0.001*NT-proBNP(pg/mL)323.12 ± 250.50368.72 ± 298.710.065cTnI(ng/ml)1.026 ± 4.1811.067 ± 3.5030.914GensiniScore37.11 ± 40.62a48.01 ± 38.16b0.003*EF(%)58 ± 7.9958 ± 8.040.495Low-Lp(a): Lp(a)<300 mg/L, High-Lp(a): Lp(a)≥300 mg/L, Values are mean ± standard deviation or n(%), BUN: Blood Urea Nitrogen, HCY: homocysteine, HDL: High-Density-Lipoprotein, LDL: Low-Density-Lipoprotein, NT-proBNP: N-Terminal Pro-Brain Natriuretic Peptide, cTnI: Cardiac troponin I, EF: Ejection Fraction, a, b are markers of difference between the groups, the same letter indicates that the difference between the two groups is not statistically significant, and different letters indicate that the difference is statistically significant Table 1Baseline characteristics of patients Low-Lp(a)N=353High-Lp(a)N=177 P Male(%)160(45%)71(40%)0.254Age64 ± 11.7365.±11.660.054Hypertension(%)155(44%)82(46%)0.597Diabetes(%)73(21%)41(23%)0.512Creatinine(µmol/L)69.72 ± 14.1469.15 ± 14.860.666Uric Acid(µmol/L)357.92 ± 101.70356.22 ± 100.160.855BUN(mmol/L)5.55 ± 1.905.82 ± 2.120.134Cholesterol(mmol/L)4.25 ± 1.304.39 ± 1.210.221Triglycerides(mmol/L)1.62 ± 1.021.63 ± 1.010.973HDL(mmol/L)1.20 ± 0.371.16 ± 0.330.276LDL(mmol/L)2.69 ± 0.912.85 ± 0.990.065HCY(µmol/L)12.58 ± 5.68a14.52 ± 6.89b0.001*NT-proBNP(pg/mL)323.12 ± 250.50368.72 ± 298.710.065cTnI(ng/ml)1.026 ± 4.1811.067 ± 3.5030.914GensiniScore37.11 ± 40.62a48.01 ± 38.16b0.003*EF(%)58 ± 7.9958 ± 8.040.495Low-Lp(a): Lp(a)<300 mg/L, High-Lp(a): Lp(a)≥300 mg/L, Values are mean ± standard deviation or n(%), BUN: Blood Urea Nitrogen, HCY: homocysteine, HDL: High-Density-Lipoprotein, LDL: Low-Density-Lipoprotein, NT-proBNP: N-Terminal Pro-Brain Natriuretic Peptide, cTnI: Cardiac troponin I, EF: Ejection Fraction, a, b are markers of difference between the groups, the same letter indicates that the difference between the two groups is not statistically significant, and different letters indicate that the difference is statistically significant Baseline characteristics of patients Low-Lp(a): Lp(a)<300 mg/L, High-Lp(a): Lp(a)≥300 mg/L, Values are mean ± standard deviation or n(%), BUN: Blood Urea Nitrogen, HCY: homocysteine, HDL: High-Density-Lipoprotein, LDL: Low-Density-Lipoprotein, NT-proBNP: N-Terminal Pro-Brain Natriuretic Peptide, cTnI: Cardiac troponin I, EF: Ejection Fraction, a, b are markers of difference between the groups, the same letter indicates that the difference between the two groups is not statistically significant, and different letters indicate that the difference is statistically significant After a 3-year follow-up (mean 33 months), a total of 93 Major Adverse Cardiovascular Events were recorded, including 58 acute cardiovascular events, 4 cardiac deaths, 21 non-fatal strokes or infarctions, 50 angina-related hospitalizations, and 70 unplanned revascularizations. When stratified by Lp(a) concentration into High-Lp(a) and Low-Lp(a) groups, the High-Lp(a) group showed significantly higher rates of MACE and ACE compared to the Low-Lp(a) group (P < 0.001).Further analysis of individual events revealed no significant differences between the groups for cardiac death (P = 0.348) or non-fatal stroke/infarction (P = 0.077). However, the incidence of angina-related hospitalization (P < 0.001) and unplanned revascularization (P = 0.001) was significantly higher in the High-Lp(a) group than in the Low-Lp(a) group, with statistically significant differences (Table 2). Table 2Incidence of endpoint events in patients with different Lp (a) concentrationsEndpoint eventsHigh-Lp(a)(n = 177)Low-Lp(a)(n = 353) P MACE48(27.12%)45(12.75%)< 0.001ACE34(19.21%)24(6.80%)< 0.001Cardiac death3(1.69%)1(0.28%)0.348Non-fatal MI or ischemic stroke9(5.08%)12(3.40%)0.077Hospitalization related to UA31(17.51%)19(5.38%)< 0.001Unplanned coronary revascularization36(20.34%)34(9.63%)0.001MACE Major adverse cardiovascular events, ACE Acute cardiovascular events* Multiple events from the same patient were included Table 2Incidence of endpoint events in patients with different Lp (a) concentrationsEndpoint eventsHigh-Lp(a)(n = 177)Low-Lp(a)(n = 353) P MACE48(27.12%)45(12.75%)< 0.001ACE34(19.21%)24(6.80%)< 0.001Cardiac death3(1.69%)1(0.28%)0.348Non-fatal MI or ischemic stroke9(5.08%)12(3.40%)0.077Hospitalization related to UA31(17.51%)19(5.38%)< 0.001Unplanned coronary revascularization36(20.34%)34(9.63%)0.001MACE Major adverse cardiovascular events, ACE Acute cardiovascular events* Multiple events from the same patient were included Incidence of endpoint events in patients with different Lp (a) concentrations MACE Major adverse cardiovascular events, ACE Acute cardiovascular events * Multiple events from the same patient were included Patients were subsequently categorized into three groups based on their HCY concentration quartiles: S1 (HCY < 8.85 µmol/L), S2 (8.85 ≤ HCY < 15.79 µmol/L), and S3 (HCY ≥ 15.79 µmol/L). Kaplan-Meier survival curves were used to assess the association between elevated Lp(a) and cardiovascular outcomes. Overall analysis revealed a significant association between elevated Lp(a) and the incidence of MACE and ACE (P = 0.001).In the S2 group, elevated Lp(a) was significantly associated with the occurrence of both MACE and ACE (P = 0.036 and P = 0.014, respectively). Similarly, in the S3 group, elevated Lp(a) was also linked to an increased risk of MACE and ACE (P = 0.010 and P = 0.011, respectively). However, in the S1 group, elevated Lp(a) showed no significant association with MACE or ACE occurrence (P > 0.05) (Figs. 2, 3, 4 and 5).Fig. 2The Kaplan–Meier survival curves analysis of the entire sample.The value inside represents the number of people at risk The Kaplan–Meier survival curves analysis of the entire sample.The value inside represents the number of people at risk Fig. 3The Kaplan–Meier survival curves analysis of S1. S1:HCY8.85